| Overview |
| bs-0341r-bf594-100ul |
| CXCR3 Polyclonal Antibody, AbBy Fluor® 594 Conjugated |
| WB, FCM, IF(IHC-P), IF(IHC-F), IF(ICC) |
| This antibody is specific for isoform 2: CXCR3B |
| Human, Mouse |
| Specifications |
| AbBy Fluor® 594 |
| Rabbit |
| KLH conjugated synthetic peptide derived from human CXCR3 isoform 2 |
| 1-100/415 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 2833 |
| P49682 |
| Cell membrane |
| GPR9; MigR; CD182; CD183; Mig-R; CKR-L2; CMKAR3; IP10-R; C-X-C chemokine receptor type 3; CXC-R3; CXCR-3; G protein-coupled receptor 9; Interferon-inducible protein 10 receptor; IP-10 receptor; CXCR3 |
| Isoform 1: Receptor for the C-X-C chemokine CXCL9, CXCL10 and CXCL11 and mediates the proliferation, survival and angiogenic activity of human mesangial cells (HMC) through a heterotrimeric G-protein signaling pathway (PubMed:12782716). Binds to CCL21. Probably promotes cell chemotaxis response. Isoform 2: Receptor for the C-X-C chemokine CXCL4 and also mediates the inhibitory activities of CXCL9, CXCL10 and CXCL11 on the proliferation, survival and angiogenic activity of human microvascular endothelial cells (HMVEC) through a cAMP-mediated signaling pathway (PubMed:12782716). Does not promote cell chemotaxis respons. Interaction with CXCL4 or CXCL10 leads to activation of the p38MAPK pathway and contributes to inhibition of angiogenesis. Overexpression in renal cancer cells down-regulates expression of the anti-apoptotic protein HMOX1 and promotes apoptosis. Isoform 3: Mediates the activity of CXCL11. |
| Application Dilution |
| WB |
1:300-5000 |
| FCM |
1:20-100 |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz